Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACALS: Acamprosate in C9orf72-Mutated ALS
NCT07204977Phase 1Recruiting
- Sponsor
- National Institute of Neurological Disorders and Stroke
- Start
- Feb 2026
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of acamprosate in amyotrophic lateral sclerosis (ALS), sponsored by National Institute of Neurological Disorders and Stroke. Primary endpoint: Adverse Events at 6 months. Started Feb 2026; status: recruiting.
02
Drugs
acamprosate
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT07204977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07204977.